Abstract:Merozoite surface protein 1 of Plasmodium falciparum (PfMSP-1) is regarded as a key candidate antigen for malaria vaccine development. It exhibits significant antigenic polymorphism and has been divided into 17 building blocks based on the analysis of sequence diversity. Differences in the antigenic composition of PfMSP-1 in local P. falciparum populations may result in differences in the efficacy of vaccines, which contain sequences of particular allelic variant(s) of PfMSP-1. To contribute to the required knowledge of genetic diversity of malaria parasites in geographically diverse regions, we have used the polymerase chain reaction (PCR) to analyze the sequence diversity of blocks 1–4 of PfMSP-1 in disease isolates from the Kilombero District in Tanzania. In the semi-conserved block 1, in which dimorphic amino acid variances have been described at three positions, we found three of the five previously described combinations of these three pairs of amino acids. In addition one combination was found, which has not been reported before in parasite isolates from different locations worldwide. Of the two sequence variants, which were dominating, one (S44-Q47-V52) corresponded to the 83.1 sequence incorporated into the SPf66 malaria peptide vaccine, while the other one (G44-H47-I52) differed from the previous in all three dimorphic amino acids. The partial protection observed in a phase III SPf66 trial conducted in the Kilombero District in children aged 1–5, thus does not seem to be associated with a clear dominance of favourable variants of block 1 of PfMSP-1 in this area. All three different principle types of block 2, the major polymorphic region of PfMSP-1, were found in the Tanzanian isolates. Most of the sequences contained K1-type tripeptide repeats, but clones with MAD20-type repeats or no repetitive sequence (RO33-type block 2) were also present. K1- and MAD20-type tripeptide repeat motifs were never mixed within one parasite clone. In one sequence a hexapeptide repeat was found at the end of block 2, which has not been reported before. Dimorphism in 13 of the 17 previously described variable positions of the semi-conserved block 3 and three of four recombination types of block 4 (K/K, M/K and M/M) were found among the Tanzanian isolates. Apart from previously described dimorphic amino acid positions, polymorphism was rare in the non-repeated building blocks. Selection and spreading of parasite variants, which contain amino acid exchanges at other than the dimorphic positions thus, is not a common event. Parasite isolates frequently harboured more than one PfMSP-1 allele. Three of the four heterogeneous isolates analysed contained two different general types of sequences. One isolate contained at least four distinct clones, demonstrating the high endemicity of malaria in the Kilombero District, which is a well-established site for malaria vaccine field trials.

Expression of Plasmodium falciparum Glutamic Acid‐Rich Protein (PfGARP) in Recombinant Pichia pastoris for Malaria Vaccine Development

Evaluation of Three Pichia Pastoris-Expressed Plasmodium Falciparum Merozoite Proteins As A Combination Vaccine Against Infection with Blood-Stage Parasites

Construction of Transgenic Plasmodium Berghei As a Model for Evaluation of Blood-Stage Vaccine Candidate of Plasmodium Falciparum Chimeric Protein 2.9.

Expression of Pf332-DBL Region of Plasmodium Falciparum Membrane Protein in Pichia Pastoris

Application of a Scalable Plant Transient Gene Expression Platform for Malaria Vaccine Development

Fusion of Two Malaria Vaccine Candidate Antigens Enhances Product Yield, Immunogenicity, and Antibody-Mediated Inhibition of Parasite Growth in Vitro

[Synthesis and Expression of 42 Kd C-terminal Region of the Major Merozoite Surface Protein (MSP1 - 42) of P. Falciparum 3D7 Strain in Pichia Pastoris].

Rice‐produced MSP142 of Plasmodium Falciparum Elicits Antibodies That Inhibit Parasite Growth in Vitro

Identification of cultivation condition to produce correctly folded form of a malaria vaccine based on Plasmodium falciparum merozoite surface protein-1 in Escherichia coli

In vitro production of infectious Plasmodium falciparum sporozoites

Blood-Stage Vaccine Candidate of Plasmodium Falciparum

A Direct and Rapid Sequencing Strategy for the Plasmodium Falciparum Antigen Gene Gp190/msa1

Expression and the Immune Response of the EGF2 Domain in the Merozoite Surface Protein 1 of Plasmodium Faciparum

Generation of a transgenic P. cynomolgi parasite expressing P. vivax circumsporozoite protein for testing pre-erythrocytic malaria vaccines in non-human primates

In Vitro Expression and in Vivo Immunogenicity of Plasmodium Falciparum Pre-Erythrocytic Stage DNA Vaccines.

Construction of a Vaccinia Virus Vectored Multi-Epitope Vaccine Candidate for Plasmodium Falciparum

Systematic Analysis of Natural Antibody Responses to P. Falciparum Merozoite Antigens by Protein Arrays.

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

[Construction and Expression of Plasmodium Berghei Chimeric Protein in Pichia Pastoris and Its Immunogenicity in Mice].

Constructing a Pre-Erythrocytic Multi-Epitope Chimeric Antigen of Plasmodium Falciparum and Its Expression in Pichia Pastoris

The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P. falciparum